NR1H4 and chronic kidney disease: For example, while FXR receptor agonists have been approved or are in phase 2 and 3 clinical trials for metabolic dysfunction-associated steatohepatitis,114 only one clinical trial has been conducted in DN, and no trials have been undertaken to assess the effectiveness of FXR agonists for CKD.